Carbone, D. P., Reck, M., & Steins, M. (2017). First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England journal of medicine, 376(25), . https://doi.org/10.1056/NEJMoa1613493
Chicago-Zitierstil (17. Ausg.)Carbone, David P., Martin Reck, und Martin Steins. "First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer." The New England Journal of Medicine 376, no. 25 (2017). https://doi.org/10.1056/NEJMoa1613493.
MLA-Zitierstil (9. Ausg.)Carbone, David P., et al. "First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer." The New England Journal of Medicine, vol. 376, no. 25, 2017, https://doi.org/10.1056/NEJMoa1613493.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.